Form 4: Zomedica CEO Larry Heaton II Granted 4 Million Stock Options

Zomedica Corp. CEO and Director Larry C. Heaton II was granted 4 million stock options with an exercise price of $0.05, vesting over four years.

Summary

• Larry C. Heaton II, the Chief Executive Officer and Director of Zomedica Corp. (ZOMDF), was granted 4,000,000 stock options.
• The options have an exercise price of $0.05 per share.
• The transaction date for this grant was June 12, 2025.
• The options will vest over a period, with one-quarter (1,000,000 options) vesting on the first anniversary of the grant date, which is June 12, 2026.
• The remaining options will vest monthly at a rate of 1/48th until fully vested on June 11, 2029.
• The expiration date for these stock options is June 11, 2035.
• Following this reported transaction, Mr. Heaton directly beneficially owns 4,000,000 derivative securities.

Sentiment

Score: 7

Explanation: The grant of stock options to the CEO is generally viewed positively as it aligns management's interests with shareholders, providing an incentive for long-term performance. However, it is a standard compensation disclosure rather than a significant operational or financial announcement.

Positives

• The grant of 4,000,000 stock options to the CEO, Larry C. Heaton II, aligns management's long-term incentives with shareholder value creation.
• The exercise price of $0.05 per share is relatively low, providing significant potential upside for the CEO if the company's stock price appreciates.

Risks

• The value of the granted options is entirely dependent on Zomedica Corp.'s common stock price exceeding the $0.05 exercise price in the future.
• Potential future dilution for existing shareholders if all 4,000,000 options are exercised by the CEO.

Future Outlook

NA

Industry Context

This Form 4 filing is a routine disclosure of an insider equity transaction and does not provide broader industry context or trends. It reflects a compensation event for a key executive within the company.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also potential benefit from increased management incentive to drive stock price appreciation.
• Management (Larry C. Heaton II): Significant financial incentive tied to the long-term performance and stock price of Zomedica Corp.

Next Steps

• Continued vesting of the granted stock options according to the specified schedule until June 11, 2029.
• Potential exercise of options by Larry C. Heaton II at or after vesting, prior to the expiration date of June 11, 2035.

Key Dates

Keywords

Zomedica Corp., ZOMDF, Larry C. Heaton II, Stock Options, CEO Compensation, SEC Form 4, Insider Trading, Beneficial Ownership, Equity Grant, Vesting Schedule